C5

Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Jeudi, mai 2, 2024
FDA, Efficacy, Inflammation, DSM-IV codes, C5, Research, Abstract, Geographic atrophy, Paratriathlon, Primate, Sodium iodate, Immunoassay, AAV, Retina, ONL, Patient, Neurology, PALO, Kriyā, Mouse, Annual general meeting, Therapy, ARVO, Vaccine

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Key Points: 
  • PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.
  • Kriya’s pipeline includes gene therapies across several therapeutic areas including ophthalmology, metabolic disease and neurology.
  • Broad coverage was achieved from the injection site to the posterior pole, including the macula and retina.
  • The study demonstrates, in a dose dependent manner, the potential of AAV.CR2-CR1 to preserve the photoreceptor-containing outer nuclear layer (ONL).

CEX.IO’s Mark Taylor, Global Head of Financial Crime to Join Panel Organized by C5

Retrieved on: 
Mardi, avril 23, 2024
Crypto, Decentralized finance, Public sector, Recovery, Ecosystem, Fraud, C5, Financial crime, Private, Environment, Database, The Fight, Cryptocurrency

Panelists will explore successful attempts at digital asset recovery, and reveal the necessary levers required for cross-platform and multi-jurisdictional collaboration to assist in these efforts.

Key Points: 
  • Panelists will explore successful attempts at digital asset recovery, and reveal the necessary levers required for cross-platform and multi-jurisdictional collaboration to assist in these efforts.
  • The panel will take place on Friday, 26 April from 12:45 - 13:30 at The Millennium Gloucester Hotel, 4-18 Harrington Gardens, South Kensington, London.
  • “For too long, bad actors have felt empowered to exploit undefined parameters in the crypto ecosystem, often at the disadvantage of unsuspecting participants,” Taylor said.
  • Launched by C5 , Crypto and Digital Asset Fraud & Recovery aims to unite people power with data-driven solutions in an effort to build more harmonious online spaces.

Ampace C5 Transforms Commercial and Industrial Energy Storage

Retrieved on: 
Vendredi, avril 19, 2024
GT40, PV, Cell, C5, Explosion, Safety, Partnership, ESS, Life, IDC, CIES, Ageing, Temperature, Growth, Renewable energy

DUBAI, UAE, April 19, 2024 /PRNewswire/ -- Ampace has unveiled its latest innovation recently, the Ampace C5, an all-in-one energy storage facility for commercial and industrial applications, marking a significant step in advancing sustainable energy solutions.

Key Points: 
  • DUBAI, UAE, April 19, 2024 /PRNewswire/ -- Ampace has unveiled its latest innovation recently, the Ampace C5, an all-in-one energy storage facility for commercial and industrial applications, marking a significant step in advancing sustainable energy solutions.
  • Compared to auxiliary sources, it reduces operational costs by 46 percent over ten years, setting a new standard for energy storage in commercial and industrial sectors.
  • With its outstanding technical performance, Ampace C5 delivers a cost-effective and reliable energy solution, presenting significant profit opportunities for users.
  • In the realm of energy storage, e-mobility, power tools, vacuum cleaners, drones, and more, Ampace has established extensive strategic partnerships with industry leaders.

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Lundi, avril 1, 2024
Diagnosis, Civil service commission, Research, AATD, Growth, Akari, C5, Patient, Choroidal neovascularization, Sale, B4, PRV, Mortality, Hot game, Clinical trial, Therapy, Priority review, Safety, NEI, European Commission, ADC, Geographic atrophy, Hematopoietic stem cell transplantation, CNV, Pharmaceutical industry

BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

Key Points: 
  • BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.
  • The combined entity will operate as Akari Therapeutics, Plc, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX.
  • Akari is continuing to recruit patients into the Part A portion of the Phase 3 clinical trial that has treated 10 patients to date.
  • During 2023, Akari also advanced the long-acting version of nomacopan (PASylated nomacopan) into the final stages of pre-clinical development as a treatment for geographic atrophy (GA).

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Retrieved on: 
Lundi, avril 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Factor D, Arthralgia, Chest pain, Confusion, Neuropsychological test, Infection, Eculizumab, Risk, Headache, ALPHA, PNH, C5, Patient, Orphan, Mitigation, Vaccine, Light, Paroxysmal nocturnal hemoglobinuria, EVH, Bacteria, University, Chills, MD, Breakthrough therapy, Cough, European Medicines Agency, Fatigue, Nausea, Rash, Fever, Priority, Safety, Immune system, REMS, Division, Vomiting, Hematology, Patient safety, Medicine

VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.

Key Points: 
  • VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.
  • You must complete or update meningococcal vaccine(s) and streptococcus vaccine(s) at least 2 weeks before your first dose of VOYDEYA.
  • If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting VOYDEYA.
  • Carry it with you at all times during treatment and for 1 week after your last VOYDEYA dose.

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mardi, mars 12, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Pregnancy, Administration, Risk, C5, Patient, Corporation, Acquisition, EMA, European Medicines Agency, Woman, Injection site reaction, Research and development, Clinical trial, Workforce, Pharmacokinetics, Safety, Antiphospholipid syndrome, Data, Pharmaceutical industry

The workforce reduction included 19 roles and will be substantially complete by the end of the first quarter of 2024.

Key Points: 
  • The workforce reduction included 19 roles and will be substantially complete by the end of the first quarter of 2024.
  • In November 2023, Rallybio announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study for RLYB212.
  • Research & Development (R&D) Expenses: R&D expenses were $15.9 million for the fourth quarter of 2023, compared to $10.8 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $5.2 million for the fourth quarter of 2023, compared to $6.3 million for the same period in 2022.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Mardi, mars 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Retrieved on: 
Mardi, mars 5, 2024
Therapy, DLA Piper, Leukotriene B4, NEI, C5, CNV, OTC, Inflammation, Bayer, Choroidal neovascularization, ADC, Risk, AATD, American depositary receipt, Geographic atrophy, Haematopoietic system, Patient, Autoimmunity, McKinsey & Company, Hot game, LTB4, Cancer, Pharmaceutical industry

Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.

Key Points: 
  • Following closing, the company will have an expanded pipeline that contains multiple compelling assets spanning early and late development stages.
  • An assessment of the pipeline is planned, including program prioritization, updated timelines, near-term value creation opportunities, and other considerations.
  • Key highlights of the merger include:
    The merged pipeline features a robust ADC toolkit with novel payload and linker technologies.
  • Goodwin Procter LLP is serving as legal advisor to Akari and DLA Piper LLP is serving as legal advisor to Peak Bio.

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Retrieved on: 
Jeudi, janvier 4, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Science, Conference, Geographic atrophy, Food, GMG, Risk, Woman, EMA, Paratriathlon, Data, Injection site reaction, AbCellera, HPP, Antiphospholipid syndrome, European Medicines Agency, Pregnancy, Corporation, DSM-IV codes, C5, Hypophosphatasia, ENPP1, Investment, Webcast, Patient, Therapy, Pharmaceutical industry

Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.

Key Points: 
  • Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.
  • Rallybio expects to complete this manufacturing work and provide an update on the development plan for RLYB116 in the second half of 2024.
  • Rallybio and EyePoint expect to provide an update on this collaboration in the first half of 2024.
  • Rallybio and Exscientia plan to provide an update on the progress of the program in the second half of 2024.

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Patient, Medical Subject Headings, Marketing, Protein, Risk, Immune system, Infection, ATC, Neisseria meningitidis, Paroxysmal nocturnal hemoglobinuria, Bleeding, PNH, Disease, Headache, Pharmacist, LDH, Language, Vaccination, Medicine, Blood, Laboratory, European Medicines Agency, C5, Select, Cell, Safety, Hemolysis, Bacteria, Anatomy, Paroxysmal attack, Anemia, Hematology, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Epysqli, Date of authorisation: 26/05/2023, Revision: 1, Status: Authorised